Cargando…

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis

BACKGROUND: T cell receptor-engineered T cell (TCR-T) therapy has shown promising efficacy in advanced solid tumours. Lymphodepleting (LD) chemotherapy improves TCR-T cell therapy efficacy but is associated with significant toxicities. Evidence is sparse regarding the optimum LD regimen for TCR-T ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Owen, Kathryn, Ghaly, Ramy, Shohdy, Kyrillus S., Thistlethwaite, Fiona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628360/ https://www.ncbi.nlm.nih.gov/pubmed/36315268 http://dx.doi.org/10.1007/s00262-022-03287-1

Ejemplares similares

Prognostic Impact of Cytotoxic CD4 T Cells in Tumor Immune Microenvironment of Patients with Breast Cancer
por: Shohdy, Kyrillus S., et al.
Publicado: (2021)

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
por: Shohdy, Kyrillus S., et al.
Publicado: (2023)

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

P53. Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma
por: Kovács, J, et al.
Publicado: (2014)

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine
por: Shohdy, Kyrillus S, et al.
Publicado: (2018)

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
por: Baulu, Estelle, et al.
Publicado: (2023)

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

Availability of Informal Caregivers for Palliative Care Patients with Cancer: Is there a Difference between Higher- and Lower-Income Settings
por: Abdel-Malek, Raafat, et al.
Publicado: (2019)

Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors
por: Lo Presti, Vania, et al.
Publicado: (2020)

Emerging Strategies in TCR-Engineered T Cells
por: Wei, Fang, et al.
Publicado: (2022)

A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors
por: Li, Dandan, et al.
Publicado: (2023)

Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion
por: Habib, Jakob G., et al.
Publicado: (2023)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion
por: Knipper, Johanna A., et al.
Publicado: (2020)

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8(+) T cells
por: Gattinoni, Luca, et al.
Publicado: (2005)

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
por: De Matteis, Serena, et al.
Publicado: (2023)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Optimizing engineered TCR T cell therapy for synovial sarcoma
por: D'Angelo, Sandra, et al.
Publicado: (2015)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells
por: Tanaka, Tomohiro, et al.
Publicado: (2017)

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
por: Suryadevara, Carter M., et al.
Publicado: (2018)

TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
por: Reuß, Simone, et al.
Publicado: (2014)

Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022)

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma
por: Acosta-Medina, Aldo A., et al.
Publicado: (2023)

Patient-reported oral mucositis in solid tumour patients undergoing chemotherapy: a Ugandan experience
por: Kamulegeya, Adriane, et al.
Publicado: (2023)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
por: Abdel Azim, Hamdy, et al.
Publicado: (2018)

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)

Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor
por: Xu, Ruihan, et al.
Publicado: (2023)

The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy
por: Dawicki, Wojciech, et al.
Publicado: (2020)

Antigen‐specific TCR‐T cells from Rag2 gene‐deleted pluripotent stem cells impede solid tumour growth in a mouse model
por: Wu, Bingyan, et al.
Publicado: (2023)

Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
por: Kierkels, Guido J.J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2uqkih5ojsk6tr9c5ihud8e63r